Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fletikumab in RA Inadequate Responders to Anti-TNFa
NCT01636817Phase 2Terminated
- Sponsor
- Novo Nordisk
- Start
- Aug 2012
- Primary completion
- Nov 2014
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
A Phase 2 trial of fletikumab in rheumatoid arthritis (RA), sponsored by Novo Nordisk. Started Aug 2012; status: terminated.
02
Drugs
fletikumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01636817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01636817.